Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (symbol: ATXS) is a pioneering biopharmaceutical company dedicated to developing transformative treatments for rare and niche allergic and immunological diseases. With a mission to improve the lives of patients and families impacted by these conditions, Astria Therapeutics is at the forefront of innovative medical research and development.
The company’s lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein. This promising therapy is currently in preclinical development, targeting the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent and severe swelling. By inhibiting plasma kallikrein, STAR-0215 aims to prevent the debilitating effects of HAE, offering hope to patients worldwide.
Astria Therapeutics is also advancing another significant product candidate, STAR-0310. This monoclonal antibody OX40 antagonist is being developed to treat atopic dermatitis (AD), an immune disorder that causes chronic skin inflammation and intense itching. Currently in preclinical development, STAR-0310 targets the immune pathways involved in AD, potentially providing relief and improved quality of life for sufferers.
Recently, Astria Therapeutics has made significant strides in its research and development efforts. The company remains committed to advancing its pipeline and exploring strategic partnerships to bring these innovative therapies to market. Financially, Astria Therapeutics continues to focus on maintaining a strong balance sheet to support its ambitious research programs and clinical trials.
In addition to its core projects, Astria Therapeutics actively engages with the medical community, patient advocacy groups, and regulatory bodies to ensure its treatments meet the highest standards of efficacy and safety. By fostering these collaborations, the company aims to accelerate the delivery of breakthrough therapies to those in need.
For the latest updates on Astria Therapeutics, including news on their clinical trials, partnerships, and corporate developments, stay tuned to StockTitan.
Astria Therapeutics (NASDAQ:ATXS) announced the presentation of preclinical data for STAR-0215, a treatment for hereditary angioedema (HAE), at the 2022 ACAAI Annual Scientific Meeting in Louisville, Kentucky. The e-poster, titled "Modeling and Simulation Predicts Robust HAE Attack Suppression with Every Three Month Dosing of STAR-0215," will be presented by Jou-Ku Chung on November 13, 2022 at 12:05 PM ET. STAR-0215 aims for long-lasting prevention of HAE attacks with dosing every three months. The ongoing Phase 1a clinical trial's preliminary results are expected by year-end.
Astria Therapeutics, Inc. (NASDAQ: ATXS) announced the granting of stock options for 46,500 shares on November 1, 2022, under its 2022 Inducement Stock Incentive Plan. The options, available to new employees, have an exercise price of $10.71, matching the stock's closing price on the grant date. These options will vest over four years, with 25% vesting on the first anniversary of the employee's start date and the remainder vesting monthly. The plan aligns with Nasdaq Listing Rule 5635(c)(4) for employee inducements.
Astria Therapeutics (NASDAQ:ATXS) has announced a virtual R&D Day on September 30, focused on STAR-0215, a monoclonal antibody in clinical development for hereditary angioedema (HAE). Dr. Marc Riedl will present on HAE treatment advancements, followed by Astria's management discussing STAR-0215's development. This event aims to enhance understanding of current treatments and improve patient experiences. An archived replay will be available on their website for 30 days post-event.
Astria Therapeutics (NASDAQ:ATXS) has announced presentations at two upcoming investment conferences. CEO Jill C. Milne will give a corporate overview and discuss the lead program STAR-0215, a treatment for hereditary angioedema, at the H.C. Wainwright Global Investment Conference on September 12. She will also participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29. Archived replays of the presentations will be available on the company's website for 30 days following the events.
Astria Therapeutics, Inc. (NASDAQ:ATXS) has granted stock options to purchase 5,500 shares of common stock on September 1, 2022, under its 2022 Inducement Stock Incentive Plan. These options are designed for new employees and have an exercise price of $8.68, equivalent to the closing stock price on the grant date. The options will vest over four years, with 25% vesting after one year and the remainder monthly. This move aligns with Nasdaq Listing Rule 5635(c)(4) for inducement grants.
Astria Therapeutics (NASDAQ: ATXS) announced FDA clearance of its IND application for STAR-0215, a treatment for hereditary angioedema (HAE). The company has initiated a Phase 1a clinical trial involving 24 healthy subjects, with preliminary results expected by year-end 2022. Financial results for Q2 2022 show a net loss of $11.3 million, with R&D expenses increasing to $6.6 million. The company has $102.5 million in cash, sufficient to fund operations through 2023. Astria plans to host a virtual R&D Day on September 30, 2022, to discuss STAR-0215's development.
Astria Therapeutics (NASDAQ: ATXS) has initiated a Phase 1a clinical trial for STAR-0215, aimed at treating hereditary angioedema (HAE). This monoclonal antibody, given quarterly, is designed for long-lasting attack prevention. The trial will assess the safety and pharmacodynamics of STAR-0215 involving 24 healthy subjects across three dosing cohorts. Preliminary results are expected by year-end, with the goal of establishing clinical proof of concept. Successful outcomes could position STAR-0215 as a potential best-in-class treatment for HAE.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced that CEO Jill C. Milne, Ph.D., will present a corporate overview at the Wedbush PacGrow Healthcare Conference on August 10 at 9:10 AM ET. The focus will be on STAR-0215, an innovative therapy for hereditary angioedema in preclinical development. Attendees can access the live webcast here, with a replay available for 30 days on their website. Astria is dedicated to developing therapies for rare allergic and immunological diseases.
Astria Therapeutics, Inc. (NASDAQ: ATXS) has granted 130,000 stock options to two newly-hired employees as part of its 2022 Inducement Stock Incentive Plan. The awards, effective August 1, 2022, include a significant 100,000 options awarded to Dr. Chris Morabito, the new Chief Medical Officer, who joined the company on July 14, 2022. Each option has an exercise price of $3.87 per share and will vest over four years, contingent upon continued employment. These grants align with Nasdaq Listing Rule 5635(c)(4) regarding inducement awards.
Astria Therapeutics, Inc. (NASDAQ: ATXS) has received FDA clearance for its Investigational New Drug (IND) application for STAR-0215, a treatment for hereditary angioedema (HAE). A Phase 1a trial in healthy volunteers will start soon, with preliminary results expected by year-end. The company aims to provide effective, long-acting treatment with dosing every three months or longer. This IND acceptance marks a significant step toward clinical trials for STAR-0215, showcasing the company’s commitment to addressing unmet needs in rare allergic diseases.
FAQ
What is the current stock price of Astria Therapeutics (ATXS)?
What is the market cap of Astria Therapeutics (ATXS)?
What does Astria Therapeutics, Inc. specialize in?
What is STAR-0215?
What is hereditary angioedema (HAE)?
What is STAR-0310?
What is atopic dermatitis (AD)?
How is Astria Therapeutics funded?
Does Astria Therapeutics collaborate with other organizations?
How can I stay updated on Astria Therapeutics' latest developments?
What is the significance of STAR-0215 in treating HAE?
What are the benefits of STAR-0310 for atopic dermatitis patients?
